AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Stock Short Interest Jumps 382.9%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totaling 2,765,187 shares, a growth of 382.9% from the August 31st total of 572,582 shares. Based on an average daily volume of 11,020,474 shares, the days-to-cover ratio is currently 0.3 days. Approximately 9.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reduced their price objective on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

AIM ImmunoTech Price Performance

Shares of NYSEAMERICAN:AIM traded down $0.01 during trading on Friday, hitting $0.19. 814,255 shares of the company’s stock were exchanged, compared to its average volume of 12,478,289. The business’s 50-day simple moving average is $0.24 and its 200 day simple moving average is $0.40. The company has a market cap of $5.91 million, a price-to-earnings ratio of -0.06 and a beta of 1.19. AIM ImmunoTech has a 52-week low of $0.19 and a 52-week high of $2.88.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The company had revenue of $0.03 million during the quarter. On average, sell-side analysts anticipate that AIM ImmunoTech will post -0.78 EPS for the current fiscal year.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc is a biotechnology company focused on developing and commercializing immunomodulatory therapies for cancer, viral diseases and disorders involving the immune system. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA therapeutic designed to stimulate immune responses and is being studied in several disease settings.

AIM also owns Alferon N Injection, an interferon alfa-n3 product approved in the United States for the treatment of refractory or recurring external genital warts in adults.